Clinical trials: Cemiplimab
Cutaneous Squamous Cell Carcinoma
Real World Study on the Use of Cemiplimab in Adult Patients in UK
The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated…
- Trial name
- REACT-CEMI (NCT05493826)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 110 people
- Sponsor
- Sanofi
Head and Neck Squamous Cell Carcinoma, HNSCC
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
The purpose of this study is to evaluate the experimental immunotherapy agent cemiplimab-rwlc when given after completion of chemotherapy and radiation treatment and determine if it will improve progression free survival and cure…
- Conditions
- Head and Neck Squamous Cell Carcinoma, HNSCC, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity
- Trial name
- NCT04831450
- Testing
- Cemiplimab-Rwlc
- Sponsor
- University of Miami
Head and Neck Cancer
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer who have…
- Trial name
- NCT07179315
- Testing
- cemiplimab+fianlimab, Cemiplimab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Chicago
Non Small Cell Lung Cancer Metastatic, Lung Diseases
PALACE: Cemiplimab Trial According to ctDNA Levels
This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer
- Trial name
- PALACE (NCT06917573)
- Testing
- Cemiplimab, Carboplatin, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundación GECP
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objectives of the study are: To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell…
- Conditions
- Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT03088540
- Testing
- Pemetrexed, Paclitaxel, Gemcitabine
- Where
- 192 sites in Australia, Belarus and 22 more
- Volunteers
- 712 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT06088771
- Testing
- Dupilumab, Cemiplimab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ovarian Cancer, Fallopian Tube Cancer
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06787612
- Testing
- Ubamatamab, Bevacizumab, Cemiplimab
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 297 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Advanced Melanoma
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced…
- Trial name
- NCT07223411
- Testing
- Fianlimab + Cemiplimab, Relatlimab + Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- John Kirkwood
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Secondary Angiosarcoma, Locally Advanced Sarcoma
Cemiplimab for Secondary Angiosarcomas
Secondary angiosarcomas are aggressive mesenchymal tumors with a poor prognosis and limited therapeutic options. Recent studies conducted in patients with cutaneous squamous-cell carcinoma provide evidence that cemiplimab has the…
- Conditions
- Secondary Angiosarcoma, Locally Advanced Sarcoma, Metastasis
- Trial name
- NCT04873375
- Testing
- Cemiplimab
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Radboud University Medical Center
Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
This phase II trial studies how well cemiplimab before surgery works in treating patients with skin cancer that is high-risk and has not spread to other parts of the body (localized), has come back locally (locally recurrent), or…
- Conditions
- Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer
- Trial name
- NCT04315701
- Testing
- Cemiplimab, Resection
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
HIV Infections
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
The purpose of this study was to evaluate the safety and immunotherapeutic activity of an anti-PD-1 antibody (cemiplimab) in participants with HIV-1 on suppressive combination antiretroviral therapy (cART).
- Trial name
- NCT03787095
- Testing
- Cemiplimab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by…
- Conditions
- Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8
- Trial name
- NCT06900595
- Testing
- Biospecimen Collection, Cabozantinib, Cemiplimab
- Where
- 81 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
This phase II trial studies how well cemiplimab works before surgery in treating patients with stage II-IV head and neck cutaneous squamous cell cancer that has come back (recurrent) and can be removed by surgery (resectable).
- Conditions
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT03565783
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
A non-randomized two-cohort study of neoadjuvant Cemiplimab or neoadjuvant Cemiplimab plus Fianlimab (CF) in patients with basal cell carcinoma of the head and neck.
- Trial name
- NCT05929664
- Testing
- Cemiplimab, Computed Tomography, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Thomas Jefferson University
Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
This trial studies the side effects of short-term fasting in patients with skin malignancy that has spread to other places in the body (advanced or metastatic) treated with a PD-L1 or PD-1 inhibitor.
- Trial name
- NCT04387084
- Testing
- Atezolizumab, Avelumab, Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults.
- Trial name
- NeoSTOP-IT (NCT06571708)
- Testing
- Gemcitabine, Cisplatin, Cemiplimab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Columbia University
Melanoma (Skin)
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
- Trial name
- NCT07527325
- Testing
- Fianlimab, Cemiplimab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Melanoma
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT05608291
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,564 people
- Sponsor
- Regeneron Pharmaceuticals
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
This phase I/II trial tests the safety and efficacy of split-course adaptive radiation therapy in combination with immunotherapy with or without chemotherapy for the treatment of patients with stage IV lung cancer or lung cancer…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
- Trial name
- NCT05501665
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center